Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

Journal Articles

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Chuenlei Parng, PhD, Macy Jin, PhD, Matthew Holsti, PhD, Susan Benard, Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Alison Joyce, Rob Webster, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 2391.

https://doi.org/10.1182/blood-2019-130327

Published: 2019

Journal Articles

Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States

Adrian R Levy, Laura Dysart, Yogesh Patel, Andrew Briggs, DPhil, John Schneider, Karl-Johan Myren, MSc, Ioannis Tomazos, PhD MBA

Blood (2019) 134 (Supplement_1): 4803.

https://doi.org/10.1182/blood-2019-127443

Published: 2019

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

John D Belcher, PhD, Margaret Biddle, PhD, Domi Stickens, PhD, Lyndsay Olson, Eric Bell, Chunsheng Chen, Fuad Abdulla, Julia Nguyen, Zachary Monroe Kiser, BS, PhD, Jacob Lloyd, MD, Gregory M Vercellotti, MD

Blood (2019) 134 (Supplement_1): 983.

https://doi.org/10.1182/blood-2019-127300

Published: 2019

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Tomasz W. Kaminski, PharmD, Egemen Tutuncuoglu, MSc, Margaret V. Ragni, MD MPH, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 1043.

https://doi.org/10.1182/blood-2019-130471

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 1299.

https://doi.org/10.1182/blood-2019-130283

Published: 2019

Journal Articles

CD39 As a Master Regulator of Pulmonary Thrombosis in Sickle Cell Disease

Tomasz Brzoska, PhD, Egemen Tutuncuoglu, MSc, Stevan P. Tofovic, Edwin K. Jackson, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 2266.

https://doi.org/10.1182/blood-2019-130882

Published: 2019

Journal Articles

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Ralph V. Boccia, MD, Naomi V Dahl, PharmD, William E Strauss, MD

Blood (2019) 134 (Supplement_1): 2236.

https://doi.org/10.1182/blood-2019-126149

Published: 2019

Journal Articles

Arsenic Trioxide Synergistically Enhances the Antileukemia Activity of Bcl-2 Inhibitor ABT-199 in Acute Myeloid Leukemia

Sha Liu, Lin Chen, MD, Xiaojiao Wang, Ruihua Mi, Qingsong Yin, Ruihua Fan, Xudong Wei, PhD

Blood (2019) 134 (Supplement_1): 2555.

https://doi.org/10.1182/blood-2019-129543

Published: 2019

Journal Articles

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Tomasz Zal, PhD, Mateusz Rytelewski, PhD, Rodrigo Jacamo, PhD, Malgorzata Anna Zal, MSc, Meenakshi Shanmugasundaram, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2674.

https://doi.org/10.1182/blood-2019-131945

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Bach1 Inhibitors Reduce Stasis in Townes Sickle Cell Mouse Model

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

CD39 As a Master Regulator of Pulmonary Thrombosis in Sickle Cell Disease

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Arsenic Trioxide Synergistically Enhances the Antileukemia Activity of Bcl-2 Inhibitor ABT-199 in Acute Myeloid Leukemia

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only